Skip to content
value.today

R3 Vascular Inc.

Formerly R2 Medical Inc.

Total raised
$73 M
1 round on record
Latest round
$73 M
Apr 2024
First round on record
Apr 2024
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of R3 Vascular Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$73 MNo. 1$50 to $250 million

R3 Vascular Inc.: Raise no. 1, Apr 2024

Investors in this round

34 investors had bought by the notice of Sep 12, 2024: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$73 M (amount offered: indefinite)
Smallest investment taken
$331
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher M. Owens · Executive Officer, Director · President and Chief Executive Officer
  • Kamal M. Ramzipoor · Executive Officer · CTO, Founder
  • Amir M. Abolfathi · Director
  • David M. Neustaedter · Director
  • Frederik M. Groenewegen · Director
  • John M. Springer · Director
  • Michael M. Hurley · Director
  • Nathan M. Harrington · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher M. Owens, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 12, 2024. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • R3 Vascular Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2024).

    SEC Form D · Sep 2024

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2024

That is all the official record says: R3 Vascular Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of R3 Vascular Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 34 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by R3 Vascular Inc.
NameRoleNamed in
Christopher M. OwensPresident and Chief Executive OfficerSep 2024
Kamal M. RamzipoorCTO, FounderSep 2024
Amir M. AbolfathiDirectorSep 2024
Christopher M. OwensPresident and Chief Executive OfficerSep 2024
David M. NeustaedterDirectorSep 2024
Frederik M. GroenewegenDirectorSep 2024
John M. SpringerDirectorSep 2024
Michael M. HurleyDirectorSep 2024
Nathan M. HarringtonDirectorSep 2024